In 2016, the biotech billionaire Dr. Patrick Soon-Shiong set himself a deadline: By 2020, he would transform the fight against cancer.

With the help of a coalition of big-name companies, researchers, and physicians, Soon-Shiong vowed, he would enroll 20,000 cancer patients in clinical trials and develop an effective vaccine to treat the disease.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Moonshots are great attention getters, but actual research gets the job done. While QUILT has been sputtering along with one percent of the predicted patient enrollment and the only people Soon-Shiong’s presenting results to are VCs, good old-fashioned bench work and clinical research have provided unprecedentedly high survival rates among cancer patients.

    It’s eerily like you have to do the work before you get the results. Imagine that.

  • I think Biotech entrepreneurs need to be slightly more conservative when commenting about new developments, especially one to cure cancer. This is no Tesla and electric cars, and Patrick Soon Shiong is no Elon Musk to make extreme commentary when it’s not warranted.

Your daily dose of news in health and medicine

Privacy Policy